CanSino Biologics Chairman and CEO Xuefeng Yu was featured in an exclusive live interview on Bloomberg TV's "The China Show" on March 31, 2026. He provided insights into CanSinoBIO's 2025 performance, its innovation-driven R&D system, and global expansion strategy, outlining the company's development path and long-term strategic vision amidst industry transformation.
The company's 2025 annual results reported total revenue of RMB 1,068 million, a year-on-year increase of 26.18%. Net profit attributable to shareholders reached RMB 27.87 million, marking a return to profitability after previously experiencing losses, including RMB -383.67 million in 2024. This turnaround was achieved despite industry-wide pressure and intensifying competition, as the company focused on an "innovation-driven growth with a focus on commercialization" strategy, optimizing revenue structure and cost efficiency.
CanSinoBIO is also demonstrating strong iterative R&D capabilities. Its pneumococcal vaccine, iPneucia® (PCV13i), has been successfully commercialized, and the 24-valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV24) has begun clinical development. The absorbed diphtheria, tetanus, and acellular pertussis (DTcP) vaccine has been granted priority review, and an adolescent and adult Tdcp vaccine has completed Phase III clinical trials, aiming for full lifecycle coverage.
The company is actively pursuing a "system-level globalization" strategy, moving beyond product exports to integrated capabilities in registration, clinical development, and localized manufacturing. It is targeting emerging markets in Southeast Asia, the Middle East, and North Africa. Menhycia® has already launched in Indonesia, with supply underway, and vaccine collaboration agreements have been established with partners in Saudi Arabia to explore joint R&D and localized production models. In the first half of 2026, CanSinoBIO's overseas revenue reached RMB 150 million, contributing to its total revenue of approximately RMB 550 million for the period, a 43.8% year-on-year increase.
CanSinoBIO's infant DTcP vaccine, Tripecia® (DT3cP Infant), received NDA approval in April 2026 and began market supply in August 2026. The New Drug Application for the Td5cp vaccine for adolescents and adults has been accepted by China’s National Medical Products Administration. Additionally, the Adsorbed Tetanus Vaccine, Tetcia®, has been approved, further strengthening the adult vaccine portfolio. Pipeline advancements include PCV24, multivalent and combination vaccines, and mRNA technologies, securing future product succession and technological reserves.
